JP2020533354A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533354A5
JP2020533354A5 JP2020514916A JP2020514916A JP2020533354A5 JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5 JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
hcmv
antigen
full
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514916A
Other languages
English (en)
Japanese (ja)
Other versions
JP7770767B2 (ja
JP2020533354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/074369 external-priority patent/WO2019052975A1/en
Publication of JP2020533354A publication Critical patent/JP2020533354A/ja
Publication of JP2020533354A5 publication Critical patent/JP2020533354A5/ja
Priority to JP2023198785A priority Critical patent/JP2024026160A/ja
Application granted granted Critical
Publication of JP7770767B2 publication Critical patent/JP7770767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514916A 2017-09-13 2018-09-11 ヒトサイトメガロウイルス免疫原性組成物 Active JP7770767B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023198785A JP2024026160A (ja) 2017-09-13 2023-11-24 ヒトサイトメガロウイルス免疫原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306179 2017-09-13
EP17306179.7 2017-09-13
PCT/EP2018/074369 WO2019052975A1 (en) 2017-09-13 2018-09-11 IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198785A Division JP2024026160A (ja) 2017-09-13 2023-11-24 ヒトサイトメガロウイルス免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2020533354A JP2020533354A (ja) 2020-11-19
JP2020533354A5 true JP2020533354A5 (https=) 2021-09-30
JP7770767B2 JP7770767B2 (ja) 2025-11-17

Family

ID=60782111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020514916A Active JP7770767B2 (ja) 2017-09-13 2018-09-11 ヒトサイトメガロウイルス免疫原性組成物
JP2023198785A Pending JP2024026160A (ja) 2017-09-13 2023-11-24 ヒトサイトメガロウイルス免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023198785A Pending JP2024026160A (ja) 2017-09-13 2023-11-24 ヒトサイトメガロウイルス免疫原性組成物

Country Status (12)

Country Link
US (4) US11524069B2 (https=)
EP (1) EP3681534A1 (https=)
JP (2) JP7770767B2 (https=)
KR (2) KR20250006307A (https=)
CN (1) CN111344009A (https=)
AU (1) AU2018331874B2 (https=)
BR (1) BR112020004747A2 (https=)
IL (1) IL273120B2 (https=)
MX (1) MX2020002810A (https=)
SG (1) SG11202002174SA (https=)
WO (1) WO2019052975A1 (https=)
ZA (1) ZA202001561B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006307A (ko) 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
KR102609106B1 (ko) * 2018-12-10 2023-12-05 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
IL302397A (en) 2020-10-28 2023-06-01 Sanofi Pasteur Liposomes containing a TLR4 agonist, their preparation and uses
EP4698152A1 (en) * 2023-04-21 2026-02-25 Instar Technologies A.S. Pharmaceutical composition for vaccination against cytomegalovirus infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0463056A1 (en) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company External regulation of gene expression
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CA2699756A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infection
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
SG189176A1 (en) 2010-10-15 2013-05-31 Glaxosmithkline Biolog Sa Cytomegalovirus gb antigen
WO2012141984A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
ES2753138T3 (es) * 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
MX2015005505A (es) * 2012-10-30 2016-01-08 Redvax Gmbh Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
US20150322115A1 (en) 2014-05-08 2015-11-12 Redvax Gmbh Means and methods for treating cmv
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3347045A4 (en) * 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
FI3471760T3 (fi) * 2016-06-17 2025-01-27 Boehringer Ingelheim Vetmedica Gmbh Lineaarisia tai haaroittuneita polyakryylihappopolymeeriadjuvantteja käsittäviä uusia immunogeenisiä formulaatioita
KR20250006307A (ko) 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물

Similar Documents

Publication Publication Date Title
JP2020533354A5 (https=)
Yang et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Lin et al. Calcium phosphate nanoparticles as a new generation vaccine adjuvant
Huang et al. Research progress on emulsion vaccine adjuvants
Shah et al. Overview of vaccine adjuvants: introduction, history, and current status
HRP20160816T1 (hr) Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica
O’Hagan et al. New generation adjuvants–from empiricism to rational design
Cui et al. Vaccine adjuvants: current status, research and development, licensing, and future opportunities
JP7053106B2 (ja) リピドａ模倣体、調製方法、及びその使用
Levast et al. Vaccine potentiation by combination adjuvants
Bramwell et al. Particulate delivery systems for vaccines
Atmar et al. Adjuvants for pandemic influenza vaccines
ES2647902T3 (es) Método de administración de vacunas
Dowling et al. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox
Mata et al. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research
JP2013053146A5 (https=)
JP2009514839A5 (https=)
Zeng et al. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives
Rambe et al. Safety and mechanism of action of licensed vaccine adjuvants
Soni et al. The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems
Chae et al. Development of squalene-based oil-in-Water Emulsion adjuvants using a self-emulsifying drug delivery system for enhanced Antigen-specific antibody titers
Burakova et al. Food‐Grade Saponin Extract as an Emulsifier and Immunostimulant in Emulsion‐Based Subunit Vaccine for Pigs
Bioley et al. Long-term persistence of immunity induced by OVA-coupled gas-filled microbubble vaccination partially protects mice against infection by OVA-expressing Listeria
Chowdhury et al. Nanotechnology platform for advancing vaccine development against the COVID-19 virus
Nielsen et al. ISCOMs as a vaccine delivery system